Format

Send to

Choose Destination
Br J Pharmacol. 2006 May;148(1):4-6.

Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?

Author information

1
Department of Medicine, Cardiovascular Medicine Section, University of Wisconsin, Madison, WI 53705, USA. jcm@medicine.wisc.edu

Abstract

Ranolazine is a new antianginal drug approved for clinical use in the United States in January 2006. A study published in this same issue of the British Journal of Pharmacology characterizes ranolazine block of late sodium current caused by the long QT syndrome 3 mutations. This commentary discusses the implications of that study and the background and implications for block of late cardiac sodium current in general.

PMID:
16520741
PMCID:
PMC1617040
DOI:
10.1038/sj.bjp.0706713
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center